PepLib announced that it had completed a Series B financing round of nearly 100 million yuan.
July 23, 2025 – Hunan, China
Zonsen PepLib Biotech Inc. (PepLib) announced that it had completed a Series B financing round of nearly 100 million yuan. This marks PepLib's third round of financing following its Series A (December 2019) and Series A+ (April 2021). This funding was led by CDH Investments, the lead investor from the A+ round, with participation from Xiangjiang State Investment, Xiangjiang Shannuo Private Equity Fund (LP: Jiudian Pharmaceutical, 300705.SZ), Sheng Nuo Biotec (688117.SH), and Shangshan Daohe Private Equity Fund (LP: Jiudian Pharmaceutical, 300705.SZ), among others.
PepLib has established the industry-leading peptide-drug discovery and development platform, powered by a global R&D team and anchored by 6 proprietary and complementary screening libraries:
1.Peptide Information Compression Technology (PICT) Peptide Library
2.AI-Driven Virtual Peptide Library
3.Disulfide Rich Peptides-Phage Display (DRP-PD) Peptide Library
4.mRNA Display Peptide Library
5.Animal Toxin Peptide Library
6.Nano Macrocyclic Peptide Library
Leveraging these screening libraries,PepLib can break the global peptide-drug discovery bottleneck.
PepLib has also built 12 integrated capability platforms:
1.High-throughput screening platform
2.Virtual screening platform
3.Peptide chip screening platform
4.Structural analysis & AI drug discovery platform
5.Gene construction & peptide expression platform
6.Target-protein expression & cell line establishment platform
7.3D-cell pharmacodynamic testing platform
8.New drug blood-brain barrier permeability testing platform
9.ADME platform
10.Met-ID platform
11.Trimer primer synthesis platform
12.Peptide conjugation platform
Leveraging these platforms, PepLib can rapidly identify new high-activity peptides against any target and accelerate the progression of lead candidates through pre-clinical development.
Meanwhile, PepLib has made forward-looking layouts in the field of Peptide Drug Conjugates (PDC) and Peptide Radionuclide Conjugates (PRC). PepLib is vigorously developing PRC and PDC drugs with cyclic peptides as target molecules. So far, multiple PRC and PDC compounds under research have potent tumor specificity, with several PRC and PDC assets advancing to the PCC stage or IIT/Phase 0 trials.
The funds raised in this round will mainly be used to support the layout and advancement of PepLib's self-developed pipeline projects, the upgrade of the AI drug development platform, and the introduction of high-end talents, etc.
Statement from Lei Chen, Co-Founder & Chairman of PepLib
“We are very pleased to see that at the critical stage when PepLib is fully promoting the R&D and commercialization of its self-developed pipeline projects, it has received investment and support from this round of investors, especially industrial capital, Jiudian Pharmaceutical (300705.SZ) and Sheng Nuo Biotec (688117.SH). This fully demonstrates the high recognition of this round of investors towards the peptide innovative drug track and PepLib's future development prospects. The innovative drug industry has gone through a period of dormancy in the past few years. Currently, it is showing an accelerating development trend in terms of policy support, technological breakthroughs, and international market expansion. The PepLib's management team will continue to adhere to its strategic goals, remain confident, intensify the recruitment of R&D talents, constantly enhance the technical strength of the new peptide discovery and development platform, and accelerate the R&D and commercialization process of key pipeline projects. It is expected that this year PepLib will cooperate on multiple significant projects with MNCs.”
Statement from Xu Cao, Partner at CDH Investments
“In recent years, with the increasing difficulty in the R&D of small-molecule drugs and the homogenization trend of large-molecule drugs, peptide drugs have gradually emerged as a hot topic in the field of new drugs due to their unique advantages such as wide indications, high safety, significant efficacy, and strong specificity. With the rich experience accumulated over the years in new peptide drugs, PepLib has developed into a growth-oriented biotech with high popularity and influence in the industry. We are full of confidence and firmly optimistic about PepLib's future development prospects.”
